Haemonetics Corporation (NYSE: HAE) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk and Volatility

Haemonetics Corporation has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Earnings and Valuation

This table compares Haemonetics Corporation and MiMedx Group’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Haemonetics Corporation $887.11 million 2.71 $164.54 million $0.08 571.95
MiMedx Group $283.32 million 4.73 $32.97 million $0.19 65.69

Haemonetics Corporation has higher revenue and earnings than MiMedx Group. MiMedx Group is trading at a lower price-to-earnings ratio than Haemonetics Corporation, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Haemonetics Corporation and MiMedx Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics Corporation 1 2 3 0 2.33
MiMedx Group 1 0 3 1 2.80

Haemonetics Corporation currently has a consensus price target of $40.80, indicating a potential downside of 10.82%. MiMedx Group has a consensus price target of $16.00, indicating a potential upside of 28.21%. Given MiMedx Group’s stronger consensus rating and higher probable upside, analysts clearly believe MiMedx Group is more favorable than Haemonetics Corporation.

Profitability

This table compares Haemonetics Corporation and MiMedx Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics Corporation 0.48% 11.07% 6.54%
MiMedx Group 7.48% 15.95% 11.13%

Insider and Institutional Ownership

60.4% of MiMedx Group shares are held by institutional investors. 1.2% of Haemonetics Corporation shares are held by company insiders. Comparatively, 12.4% of MiMedx Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

MiMedx Group beats Haemonetics Corporation on 11 of the 14 factors compared between the two stocks.

About Haemonetics Corporation

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.

About MiMedx Group

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.